TACTICS-TIMI 18
2001
Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy — TIMI 18
In 2,220 patients with NSTE-ACS treated with tirofiban, an early invasive strategy reduced 6-month death, MI, or rehospitalisation for ACS compared with a conservative strategy.
Result
Efficacy: Death, nonfatal MI, or rehospitalisation for ACS at 6 monthsOR 0.78 (95% CI 0.62-0.97) · P = 0.025
Below 1 favours early invasive strategy, above 1 favours conservative strategy.
- Absolute difference
- 3.5 points
- NNT
- 29
Absolute difference and NNT are derived from the event rates.
Also reported: Death or nonfatal MI 7.3% vs 9.5% (OR 0.74). Benefit concentrated in troponin-positive patients.
- Subtopic
- early invasive strategy
- Design
- Multicentre open-label strategy RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Cannon CP, et al. N Engl J Med. 2001;344(25):1879-87.doi 10.1056/NEJM200106213442501
Discussion & critique
Open-label strategy design with benefit largely confined to higher-risk patients, and upstream tirofiban is no longer routine. Established the risk-stratified early invasive strategy for higher-risk NSTE-ACS.